Paper Details

  1. Home
  2. Paper Details

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.

Author: BursteinRami, BuseDawn C, ChengSunfa, ChouDenise E, DodickDavid W, KlattJan, KoukakisReija, LiptonRichard B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Erenumab's efficacy in reducing migraine frequency and acute medication use was not impacted by the presence of moderate-to-severe ictal allodynia in patients with chronic migraine.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ictal cutaneous allodynia, common in chronic migraine, is associated with reduced responses to acute treatment with triptans. Allodynia's impact on the efficacy of newer preventive treatments such as erenumab is unknown. METHODS: None RESULTS: Of 648 randomized individuals with baselin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/03331024211010305

データ提供：米国国立医学図書館（NLM）

Erenumab for Chronic Migraine: A Journey Through Ictal Allodynia

The world of chronic migraine, like a scorching desert landscape, can be a relentless battle against debilitating headaches. Ictal cutaneous allodynia, a heightened sensitivity to touch during a migraine attack, is a common and often challenging symptom that can reduce the effectiveness of acute migraine treatments. This study explores the impact of ictal allodynia on the efficacy of erenumab, a new preventive treatment for chronic migraine, by examining the treatment responses in patients with and without this symptom.

Erenumab's Journey Through the Desert of Chronic Migraine

The study found that erenumab, like a resourceful camel caravan navigating the desert, effectively reduced monthly migraine days and acute migraine-specific medication days in both patients with and without ictal allodynia. These findings suggest that erenumab, unlike other treatments, may be less affected by the presence of ictal allodynia, offering a potential breakthrough in the management of chronic migraine.

A Glimmer of Hope in the Desert: Effective Treatment for Chronic Migraine

This study offers a glimmer of hope in the desert of chronic migraine, indicating that erenumab may be a valuable treatment option even for individuals with ictal allodynia. This discovery, like a well-spring in a dry wasteland, provides a potential solution for a symptom that has often limited the effectiveness of migraine treatments. By understanding the efficacy of erenumab in patients with ictal allodynia, physicians can provide more effective and personalized care to those struggling with chronic migraine.

Dr.Camel's Conclusion

This study demonstrates the potential of erenumab as an effective treatment for chronic migraine, even in individuals with ictal allodynia. This discovery, like a camel caravan successfully navigating a treacherous desert, offers a promising avenue for improving the lives of those battling chronic migraine.

Date :
  1. Date Completed 2022-01-17
  2. Date Revised 2022-01-17
Further Info :

Pubmed ID

33982623

DOI: Digital Object Identifier

10.1177/03331024211010305

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.